California State Teachers Retirement System Increases Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

California State Teachers Retirement System raised its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 4.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 59,259 shares of the biotechnology company's stock after buying an additional 2,742 shares during the quarter. California State Teachers Retirement System owned about 0.09% of Blueprint Medicines worth $5,169,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC acquired a new position in shares of Blueprint Medicines in the fourth quarter valued at about $103,356,000. Norges Bank acquired a new position in shares of Blueprint Medicines in the fourth quarter valued at about $62,028,000. Jennison Associates LLC acquired a new position in shares of Blueprint Medicines in the fourth quarter valued at about $31,417,000. Rock Springs Capital Management LP increased its holdings in shares of Blueprint Medicines by 42.7% in the fourth quarter. Rock Springs Capital Management LP now owns 1,096,899 shares of the biotechnology company's stock valued at $95,672,000 after purchasing an additional 328,123 shares during the period. Finally, Wellington Management Group LLP increased its holdings in shares of Blueprint Medicines by 8.0% in the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock valued at $373,421,000 after purchasing an additional 316,754 shares during the period.

Insiders Place Their Bets

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 5,000 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $101.14, for a total transaction of $505,700.00. Following the completion of the sale, the director now owns 146,630 shares of the company's stock, valued at $14,830,158.20. This trade represents a 3.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction on Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the sale, the chief operating officer now directly owns 69,266 shares of the company's stock, valued at $6,581,655.32. The trade was a 3.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,574 shares of company stock valued at $1,465,528 over the last quarter. 4.21% of the stock is owned by insiders.

Blueprint Medicines Trading Down 0.0%

Blueprint Medicines stock traded down $0.05 during trading on Friday, reaching $127.85. 3,067,543 shares of the company were exchanged, compared to its average volume of 1,110,342. Blueprint Medicines Co. has a 52-week low of $73.04 and a 52-week high of $128.86. The company has a market capitalization of $8.26 billion, a P/E ratio of -118.38 and a beta of 0.83. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The stock's 50 day simple moving average is $95.59 and its two-hundred day simple moving average is $95.88.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). The company had revenue of $149.41 million for the quarter, compared to analysts' expectations of $158.31 million. Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The business's quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.40 EPS. On average, equities research analysts expect that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the company. JMP Securities reaffirmed a "market perform" rating on shares of Blueprint Medicines in a report on Tuesday. Guggenheim set a $132.00 target price on Blueprint Medicines in a report on Tuesday. Wolfe Research lowered Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a report on Tuesday. Morgan Stanley raised their target price on Blueprint Medicines from $102.00 to $129.00 and gave the stock an "equal weight" rating in a report on Thursday. Finally, Citizens Jmp lowered Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a report on Tuesday. Seventeen research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $129.35.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.